A Multicenter, Single-Arm, 24-Week Study of UB-421 in Combination With Optimized Background Therapy (OBT) Regimen in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection
Status: Not yet recruiting
Phase of Trial: Phase II/III
Latest Information Update: 03 Jun 2019
Price : $35 *
At a glance
- Drugs UB 421 (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors United BioPharma
- 29 May 2019 Planned number of patients changed from 30 to 10.
- 12 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 1 Sep 2019.
- 24 Oct 2017 Planned End Date changed from 1 Nov 2019 to 1 Nov 2020.